Maddy summaryS 1418 requires federal agencies to produce three reports analyzing data on threats to law enforcement officers and their well-being. The bill mandates a report on violent attacks (including ambushes) against officers, current training programs, and gaps in gear distribution; a report on adding a new category for non-criminal aggressive incidents against officers; and a report on mental health impacts and available support resources. These reports, due 270 days after enactment, will assess data collection systems, resource effectiveness, and disparities in reporting. The bill directly affects federal, state, and local law enforcement agencies by requiring them to contribute data and shape future safety policies. Its goal is to inform better resource allocation and training based on comprehensive data, not to mandate immediate changes.
Sponsored bills
Maddy summaryThis bill amends federal meat and poultry inspection laws to allow state-inspected meat and poultry products to be sold across state lines. It removes the previous restriction that limited such products to sales only within the state where they were inspected, enabling interstate commerce for products meeting state inspection standards. The bill requires the Secretary of Agriculture to permit interstate shipments of properly inspected state products and prohibits states from blocking the movement or sale of these items. It directly affects small meat and poultry producers, processors, and retailers who rely on state inspection programs instead of federal oversight. The change aims to expand market access for these businesses without altering inspection standards.
Maddy summaryThis bill prohibits "reverse payment" agreements where brand-name drug companies pay generic or biosimilar manufacturers to delay entering the market, which harms competition. It creates a presumption that such agreements are anticompetitive if a generic or biosimilar company receives value in exchange for delaying market entry, with exceptions for standard settlements involving early market entry rights or reasonable litigation expenses. The bill amends the Federal Trade Commission Act to enforce this new prohibition and requires certification of such agreements, aiming to enhance competition and lower drug costs for consumers. This would directly affect brand-name drug companies, generic manufacturers, and biosimilar biological product manufacturers.
Maddy summaryThe Stop STALLING Act empowers the Federal Trade Commission (FTC) to take action against pharmaceutical companies that submit "sham" petitions under drug approval processes. Specifically, it targets petitions that are objectively baseless and used to delay generic drug approvals, directly affecting drug manufacturers filing such petitions. The bill establishes civil penalties of up to $50,000 per day or the revenue earned from the delayed drug during the petition's review period. It creates a presumption of "sham" status if the Health Secretary determines a petition was filed primarily to delay approval, with companies able to rebut this presumption. The law does not alter FDA drug approval rules but adds FTC enforcement for unfair competition tactics.
Maddy summaryThe provided context does not include a substantive summary or bill text beyond the short title. Without details on the bill's specific provisions, mechanisms, or affected parties, a factual summary cannot be generated. The title "Interagency Patent Coordination and Improvement Act of 2025" suggests a focus on federal patent processes, but no concrete policy changes are described in the given text. For an accurate summary, the full bill language or official summary would be required.
Maddy summaryThe Drug Competition Enhancement Act (S.1040) prohibits drug manufacturers from engaging in "product hopping" - a practice where companies withdraw or disadvantage their original drug to push a newer "follow-on" version when generic or biosimilar competitors are about to enter the market. Specifically, it bans "hard switches" (officially withdrawing the original drug or destroying inventory to block generics) and "soft switches" (unfairly disadvantaging the original drug to favor the follow-on product) during a 3-year window before generic competition begins. The Federal Trade Commission (FTC) can enforce this by taking legal action against violators, seeking injunctions, or requiring disgorgement of profits gained from anti-competitive conduct. This law directly affects drug manufacturers holding approved "reference products" when generic or biosimilar applications are pending, aiming to prevent artificial barriers to lower-cost alternatives.
Maddy summaryThis bill requires the Federal Trade Commission (FTC) to study how pharmacy benefit managers (PBMs) and other intermediaries affect prescription drug prices and competition. Specifically, the FTC must report within one year on whether PBMs charge different prices to pharmacies, steer patients toward pharmacies they own, use pharmacy data for profit, or design formularies to favor expensive drugs. The bill also mandates an interim report within six months and a separate study on sole-source drug manufacturers and enforcement challenges. It does not directly change drug prices or create new regulations, but instead seeks to gather data to inform potential future policy actions. The study focuses on transparency and competition in the pharmaceutical supply chain, with no immediate price-reducing mechanisms.
Maddy summaryThis bill modifies tax reporting rules for payment platforms like Venmo or PayPal. It reinstates a higher reporting threshold, requiring third-party payment processors to report transactions only if a user's total exceeds $20,000 or 200 transactions in a year - reverting to pre-American Rescue Plan rules. The law directly affects payment processors and small businesses/freelancers who receive frequent small payments through these platforms. It takes effect for 2025 calendar years, reducing administrative burdens for low-volume transactions.
Maddy summaryThis bill requires the U.S. Department of Agriculture to conduct annual residue testing on imported organic feedstuffs shipped in bulk with a national organic program certificate, and to submit yearly reports to Congress detailing testing methods, results, and corrective actions. It directly affects importers of bulk organic feedstuffs by mandating compliance with new verification standards and prohibiting shipments that test above allowed levels of banned chemicals from being sold or labeled as organic. The Secretary of Agriculture must develop annual risk-based testing protocols (considering factors like shipment frequency and chemical risks) and take mandatory corrective actions when violations occur. The law does not change organic production standards but adds verification steps for specific imported feedstuffs to ensure compliance with existing organic regulations.
Maddy summaryThis bill, S 1326 (Food Security and Farm Protection Act), prohibits state and local governments from imposing additional production standards on agricultural products sold across state lines. It directly affects farmers, food producers, and businesses involved in interstate agricultural trade by preventing states from creating new rules for farming that occurs in another state, unless federal or the producing state's rules already cover it. Key mechanisms include banning such extra state rules and creating a federal court process for affected parties (like producers or distributors) to challenge those rules and seek damages. The law also requires courts to issue temporary injunctions against enforcement of challenged regulations while cases are resolved, unless the state proves it will likely win and would suffer severe harm without the rule.